Pathogenesis and pathophysiology of accelerated atherosclerosis in the diabetic heart

被引:41
作者
D'Souza, Alicia [1 ]
Hussain, Munir [2 ]
Howarth, Frank C. [3 ]
Woods, Niall M. [1 ]
Bidasee, Keshore [4 ]
Singh, Jaipaul [1 ]
机构
[1] Univ Cent Lancashire, Sch Forens & Invest Sci, Preston PR1 2HE, Lancs, England
[2] Univ Bradford, Div Biomed Sci, Bradford BD7 1DP, W Yorkshire, England
[3] United Arab Emirates Univ, Dept Physiol, Fac Med & Hlth Sci, Al Ain, U Arab Emirates
[4] Univ Nebraska Med Ctr, Dept Pharmacol & Expt Neurosci, Nebraska Med Ctr 98500, Omaha, NE USA
关键词
Diabetes mellitus; Coronary artery disease; Hyperglycemia; Endothelial dysfunction; NITRIC-OXIDE SYNTHASE; CORONARY-ARTERY-DISEASE; PROTEIN-KINASE-C; ENDOTHELIAL PROGENITOR CELLS; INSULIN-RESISTANCE; OXIDATIVE STRESS; ADVANCED GLYCATION; METABOLIC SYNDROME; VASCULAR-DISEASE; CARDIOVASCULAR-DISEASE;
D O I
10.1007/s11010-009-0148-8
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
It has been established that atherosclerotic coronary artery disease is more frequent and more severe in diabetic compared to non-diabetic subjects, but the reason for the excess risk of developing coronary macroangiopathy in diabetes remains incompletely characterized. Various biochemical mechanisms speculated to being at the "heart" of diabetic cardiac and coronary macroangiopathy are reviewed in the present article. In doing so, this article presents evidence that the labyrinthine interactions of hyperglycemia, insulin resistance, and dyslipidemia in diabetes result in a pro-atherogenic phenotype. Furthermore, the diabetic milieu yields a complex (dys)metabolic environment characterized by chronic inflammation, procoagulability, impaired fibrinolysis, neovascularization abnormalities, and microvascular defects that cumulatively alter blood rheology, artery structure, and homeostasis of the endothelium. The contributory influences of these factors in the pathophysiology of coronary artery disease in diabetes are also discussed.
引用
收藏
页码:89 / 116
页数:28
相关论文
共 173 条
[51]   Diabetic cardiomyopathy: Evidence, mechanisms, and therapeutic implications [J].
Fang, ZY ;
Prins, JB ;
Marwick, TH .
ENDOCRINE REVIEWS, 2004, 25 (04) :543-567
[52]  
FARAHMAND F, 2003, ATHEROSCLEROSIS HYPE, P387
[53]   Vascular endothelial dysfunction in diabetic cardiomyopathy: Pathogenesis and potential treatment targets [J].
Farhangkhoee, Hana ;
Khan, Zia A. ;
Kaur, Harkiran ;
Xin, Xiping ;
Chen, Shali ;
Chakrabarti, Subrata .
PHARMACOLOGY & THERAPEUTICS, 2006, 111 (02) :384-399
[54]   Diabetic Dyslipidemia and Atherosclerosis: Evidence from Clinical Trials [J].
Farmer, John A. .
CURRENT DIABETES REPORTS, 2008, 8 (01) :71-77
[55]  
FEENER EP, 1997, LANCET S1, V350, P9
[56]   Intravascular hemodynamic factors responsible for progression of coronary atherosclerosis and development of vulnerable plaque [J].
Feldman, CL ;
Stone, PH .
CURRENT OPINION IN CARDIOLOGY, 2000, 15 (06) :430-440
[57]   Angiogenesis: basic pathophysiology and implications for disease [J].
Felmeden, DC ;
Blann, AD ;
Lip, GYH .
EUROPEAN HEART JOURNAL, 2003, 24 (07) :586-603
[58]   Anti-inflammatory effects of the advanced glycation end product inhibitor LR-90 in human monocytes [J].
Figarola, James L. ;
Shanmugam, Narkunaraja ;
Natarajan, Rama ;
Rahbar, Samuel .
DIABETES, 2007, 56 (03) :647-655
[59]   Elevated plasma interleukin-18 is a marker of insulin-resistance in type 2 diabetic and non-diabetic humans [J].
Fischer, CP ;
Perstrup, LP ;
Berntsen, A ;
Eskildsen, P ;
Pedersen, BK .
CLINICAL IMMUNOLOGY, 2005, 117 (02) :152-160
[60]   Cardiovascular diabetology in the core of a novel interleukins classification: the bad, the good and the aloof [J].
Fisman, Enrique Z. ;
Motro, Michael ;
Tenenbaum, Alexander .
CARDIOVASCULAR DIABETOLOGY, 2003, 2 (1)